These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 36497271)
1. Galectins in Esophageal Cancer: Current Knowledge and Future Perspectives. Godefa TM; Derks S; Thijssen VLJL Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497271 [TBL] [Abstract][Full Text] [Related]
2. Vascular galectins in tumor angiogenesis and cancer immunity. Thijssen VLJL Semin Immunopathol; 2024 Jul; 46(1-2):3. PubMed ID: 38990363 [TBL] [Abstract][Full Text] [Related]
3. Vascular galectins: regulators of tumor progression and targets for cancer therapy. Thijssen VL; Rabinovich GA; Griffioen AW Cytokine Growth Factor Rev; 2013 Dec; 24(6):547-58. PubMed ID: 23942184 [TBL] [Abstract][Full Text] [Related]
4. The role of galectins‑1, 3, 7, 8 and 9 as potential diagnostic and therapeutic markers in ovarian cancer (Review). Mielczarek-Palacz A; Kondera-Anasz Z; Smycz-Kubańska M; Englisz A; Janusz A; Królewska-Daszczyńska P; Wendlocha D Mol Med Rep; 2022 May; 25(5):. PubMed ID: 35293602 [TBL] [Abstract][Full Text] [Related]
5. The Role of Galectins in Tumor Progression, Treatment and Prognosis of Gynecological Cancers. Chetry M; Thapa S; Hu X; Song Y; Zhang J; Zhu H; Zhu X J Cancer; 2018; 9(24):4742-4755. PubMed ID: 30588260 [TBL] [Abstract][Full Text] [Related]
6. Galectin Targeted Therapy in Oncology: Current Knowledge and Perspectives. Wdowiak K; Francuz T; Gallego-Colon E; Ruiz-Agamez N; Kubeczko M; Grochoła I; Wojnar J Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29320431 [TBL] [Abstract][Full Text] [Related]
7. New roles for galectins in brain tumors--from prognostic markers to therapeutic targets. Stillman BN; Mischel PS; Baum LG Brain Pathol; 2005 Apr; 15(2):124-32. PubMed ID: 15912884 [TBL] [Abstract][Full Text] [Related]
8. Prognostic factors and family history for survival of esophageal squamous cell carcinoma patients after surgery. Yuequan J; Shifeng C; Bing Z Ann Thorac Surg; 2010 Sep; 90(3):908-13. PubMed ID: 20732516 [TBL] [Abstract][Full Text] [Related]
9. Expression of chemokine receptor CXCR4 in esophageal squamous cell and adenocarcinoma. Gockel I; Schimanski CC; Heinrich C; Wehler T; Frerichs K; Drescher D; von Langsdorff C; Domeyer M; Biesterfeld S; Galle PR; Junginger T; Moehler M BMC Cancer; 2006 Dec; 6():290. PubMed ID: 17176471 [TBL] [Abstract][Full Text] [Related]
10. Revisiting Multi-Omics Data to Unravel Galectins as Prognostic Factors in Head and Neck Squamous Cell Carcinoma. Barros O; D'Agostino VG; Santos L; Ferreira R; Vitorino R Biomedicines; 2024 Feb; 12(3):. PubMed ID: 38540141 [TBL] [Abstract][Full Text] [Related]
11. Glycans and galectins in prostate cancer biology, angiogenesis and metastasis. Compagno D; Gentilini LD; Jaworski FM; Pérez IG; Contrufo G; Laderach DJ Glycobiology; 2014 Oct; 24(10):899-906. PubMed ID: 24939371 [TBL] [Abstract][Full Text] [Related]
12. Galectins-1, -3, -7, -8 and -9 as prognostic markers for survival in epithelial ovarian cancer: A systematic review and meta-analysis. Pergialiotis V; Papoutsi E; Androutsou A; Tzortzis AS; Frountzas M; Papapanagiotou A; Kontzoglou K Int J Gynaecol Obstet; 2021 Mar; 152(3):299-307. PubMed ID: 33156523 [TBL] [Abstract][Full Text] [Related]
13. Galectins in Glioma: Current Roles in Cancer Progression and Future Directions for Improving Treatment. Ajarrag S; St-Pierre Y Cancers (Basel); 2021 Nov; 13(21):. PubMed ID: 34771696 [TBL] [Abstract][Full Text] [Related]
14. Galectins and neovascularization in central nervous system tumors. D'Haene N; Maris C; Rorive S; Decaestecker C; Le Mercier M; Salmon I Glycobiology; 2014 Oct; 24(10):892-8. PubMed ID: 24861052 [TBL] [Abstract][Full Text] [Related]
15. Galectins as Emerging Glyco-Checkpoints and Therapeutic Targets in Glioblastoma. Videla-Richardson GA; Morris-Hanon O; Torres NI; Esquivel MI; Vera MB; Ripari LB; Croci DO; Sevlever GE; Rabinovich GA Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008740 [TBL] [Abstract][Full Text] [Related]
16. Engineering galectin-glycan interactions for immunotherapy and immunomodulation. Farhadi SA; Hudalla GA Exp Biol Med (Maywood); 2016 May; 241(10):1074-83. PubMed ID: 27229902 [TBL] [Abstract][Full Text] [Related]
17. Galectins in the Tumor Microenvironment: Focus on Galectin-1. Martínez-Bosch N; Navarro P Adv Exp Med Biol; 2020; 1259():17-38. PubMed ID: 32578169 [TBL] [Abstract][Full Text] [Related]
18. ESM1 Is a Promising Therapeutic Target and Prognostic Indicator for Esophageal Carcinogenesis/Esophageal Squamous Cell Carcinoma. Li J; Yang D; Zhang C; Wei S; Zhao R; Dai S; Shan B Biomed Res Int; 2022; 2022():5328192. PubMed ID: 35937390 [TBL] [Abstract][Full Text] [Related]
19. CD163 as a marker of M2 macrophage, contribute to predicte aggressiveness and prognosis of Kazakh esophageal squamous cell carcinoma. Hu JM; Liu K; Liu JH; Jiang XL; Wang XL; Chen YZ; Li SG; Zou H; Pang LJ; Liu CX; Cui XB; Yang L; Zhao J; Shen XH; Jiang JF; Liang WH; Yuan XL; Li F Oncotarget; 2017 Mar; 8(13):21526-21538. PubMed ID: 28423526 [TBL] [Abstract][Full Text] [Related]
20. Galectin-8 and -9 as prognostic factors for cervical cancer. Beyer S; Wehrmann M; Meister S; Kolben TM; Trillsch F; Burges A; Czogalla B; Schmoeckel E; Mahner S; Jeschke U; Kolben T Arch Gynecol Obstet; 2022 Oct; 306(4):1211-1220. PubMed ID: 35377045 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]